درباره این اپیزود
In this latest episode of Med Tech Talks, Robert Klupacs is joined by Dr Andrew Nash, former CSO of CSL.
CSL is an Australian success story and one of the world’s leading biotechnology companies. CSL has a remarkable history spanning over a century, and a global reputation for developing and delivering life-saving medicines, particularly in immunology, haematology, and vaccines.
As Chief Scientific Officer, Andrew led CSL’s global research and early development strategy, playing a pivotal role in advancing innovative therapies from discovery through to clinical development, and ultimately to patients around the world.
Today, Andrew is a Director of: The Garvan Institute of Medical Research, the Burnet Institute, ASX listed Arovella, Jumar Incubator, Brandon Capital’s BioCatalyst and also part of the Bionics Institute’s own Industry Advisory Committee.
In this episode, you will learn from Andrew about:
- Andrew's journey from academia to CSO of CSL
- His thoughts on the opportunity for innovation in Australia
- What Andrew would recommend to aspiring med tech and bio tech enterpreneurs to be successful
Learn more about Dr Andrew Nash
Updated version 05/08/22
